Revance absorbs $8M for topical Botox
Aesthetic drug developer Revance Therapeutics has landed $8 million in venture debt financing from Leader Ventures and Horizon Technology Finance. The money will be used to push its lead compound, a topical form of botulinum toxin type A (popularly known as Botox), through clinical stage trials.
While the injected form of the chemical has gained notoriety in the media, in reality, only about 10 percent of the targeted market (about 25 million women) has used it. Health concerns and discomfort have dissuaded many. The Mountain View, Calif.-based company aims to resolve these issues by providing a topical treatment that could produce the same results. In addition to the treatment itself, Revance is also testing its TransMTS technology, which allows the large botulinum molecules to cross into the skin.
Revance has raised $64 million to date, with contributors including Bio*One Capital, Essex Woodlands Healthcare Ventures, Palo Alto Investors, Medicis Pharmaceutical Corp. and Pac-Link Ventures.
Next Story: Glam launches GlamApps, a sort of Facebook for advertisers
Previous Story: Boxee raises funding as it goes after content, your living room
About the Author, Camille Ricketts
Camille is the lead writer for GreenBeat. She came to VentureBeat from Google where she worked on its traditional platforms team, particularly in TV. Before that, she was a reporter for the Wall Street Journal in New York and London. Follow her on Twitter at @camillericketts, and follow VentureBeat on Twitter at @venturebeat.